View Clinical Trial (Medical Research Study)
Prevalence of Cytomegalovirus, Epstein Barr Virus and Human Herpes 6 Virus in Inflammatory Bowel Disease - NCT00222378-33136(Clinical Trial 130921)
ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.
| City: |
|
Miami |
|
State:
|
|
FL |
| Zip Code: |
|
33136 |
| Conditions: |
|
Crohn's Disease - Ulcerative Colitis |
| Purpose: |
|
An increase prevalence of CMV, EBV and or HHV-6 in diseased tissue of inflammatory bowel
disease would suggest a role for these viruses in the etiology and/or exacerbation of IBD,
whereas their absence would preclude such association.
|
| Study summary: |
|
The protocol is designed to evaluate the following objectives:
1. The prevalence of cytomegalovirus, Epstein Barr virus and human herpes 6 virus DNA in
inflamed intestinal mucosa of patients with Crohn’s colitis and ulcerative colitis
compared to their prevalence in healthy intestinal mucosa of patients not affected by
these conditions;
2. To evaluate the prevalence of cytomegalovirus, Epstein Barr virus and human herpes 6
virus DNA in the intestinal mucosa of patients with Crohn’s colitis and ulcerative
colitis compared to that in inflamed mucosa caused by other conditions (non specific
colitis);
3. To compare the prevalence of cytomegalovirus, Epstein Barr virus and human herpes 6
virus DNA in inflamed and healthy tissue in the same patients with Crohn’s colitis and
ulcerative colitis;
4. To determine whether the presence of cytomegalovirus, Epstein Barr virus and human
herpes 6 virus DNA detected by nPCR correlates with immunohistochemical detection of
viral protein in colonic tissue.
5. To determine whether the relative viral quantity of CMV, EBV or HHV-6 is related to
severity of disease activity. |
| Criteria: |
|
Inclusion Criteria:
- Documented, signed and dated informed consent to participate in this trial prior to
any study related procedures being performed.
- Participants, male or female, aged 18-70, identified as having Crohn’s colitis, UC
and patients undergoing biopsy for other inflammatory disorders (non specific
colitis) and for suspected intestinal malignancy.
Exclusion Criteria:
- Known human immunodeficiency virus (HIV) infection
- Post organ transplant patients. |
|
|
|
| Study is available at: |
|
Jackson Memorial Hospital
Miami, FL 33136
United States
Primary Contact:
Paul A Feldman, M.D., M.Sc
Email: pfeldman@um-jmh.org
Phone: 305-585-5126
Secondary Contact:
Paul A Feldman, M.D., M.Sc.
Email: pfeldman@um-jmh.org
Phone: 305 585-5126 |
|
|
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
|
| Trials Alerts: |
|
If you would like to be
notified of new clinical trials as they become available please
register for a free account.
|
|
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
March 21, 2011 |
Modifications to
this listing: |
|
Only selected fields are shown, please use the link
above to view all information about this clinical trial. |
|
|
|
|
|
|
|
|